Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIVINE: SBRT and ARPI/ADT in Recurrent Prostate Cancer
NCT06378866Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jun 2024
- Primary completion
- Feb 2031
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) (4 arms), sponsored by Mayo Clinic. Primary endpoints: Modified radiographic progression-free survival at 5 years and Distant progression-free survival at 5 years. Started Jun 2024; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06378866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06378866.